Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative ...
Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HE ...
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...
Warszawa (2) Wojskowy Instytut Medyczny,Państwowy Instytut Badawczy Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie ...
Dr. Spring commented, "We are excited to offer the FLAMINGO-01 trial at MGH for patients with high-risk HER2-positive breast ...
Severance season two premieres tomorrow (January 17) on Apple TV+ with episodes airing weekly on the streaming platform with a total of 10 new instalments. The trailer for season two saw Mark S ...
Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...
Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive breast cancer. Long-term follow-up showed a continued DFS benefit with ado-trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback